- Home
- QLGN vs ENVB Comparison
QLGN vs ENVB Comparison
Compare QLGN & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- ENVB
- Stock Information
- Founded
- QLGN 1996
- ENVB 1994
- Country
- QLGN United States
- ENVB United States
- Employees
- QLGN N/A
- ENVB N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- ENVB Health Care
- Exchange
- QLGN Nasdaq
- ENVB Nasdaq
- Market Cap
- QLGN 3.1M
- ENVB 2.7M
- IPO Year
- QLGN N/A
- ENVB N/A
- Fundamental
- Price
- QLGN $1.90
- ENVB $1.10
- Analyst Decision
- QLGN
- ENVB Strong Buy
- Analyst Count
- QLGN 0
- ENVB 1
- Target Price
- QLGN N/A
- ENVB $10.00
- AVG Volume (30 Days)
- QLGN 125.5K
- ENVB 130.4K
- Earning Date
- QLGN 08-26-2025
- ENVB 08-14-2025
- Dividend Yield
- QLGN N/A
- ENVB N/A
- EPS Growth
- QLGN N/A
- ENVB N/A
- EPS
- QLGN N/A
- ENVB N/A
- Revenue
- QLGN N/A
- ENVB N/A
- Revenue This Year
- QLGN N/A
- ENVB N/A
- Revenue Next Year
- QLGN N/A
- ENVB N/A
- P/E Ratio
- QLGN N/A
- ENVB N/A
- Revenue Growth
- QLGN N/A
- ENVB N/A
- 52 Week Low
- QLGN $1.61
- ENVB $1.01
- 52 Week High
- QLGN $11.50
- ENVB $8.95
- Technical
- Relative Strength Index (RSI)
- QLGN 32.76
- ENVB 37.45
- Support Level
- QLGN $1.61
- ENVB $1.11
- Resistance Level
- QLGN $1.91
- ENVB $1.13
- Average True Range (ATR)
- QLGN 0.16
- ENVB 0.06
- MACD
- QLGN -0.01
- ENVB -0.01
- Stochastic Oscillator
- QLGN 26.48
- ENVB 20.00
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.